Search

Your search keyword '"Maylin, S"' showing total 163 results
Start Over Author "Maylin, S"
163 results on '"Maylin, S"'

1. Depressive symptoms after hepatitis C cure and socio-behavioral correlates in aging people living with HIV (ANRS CO13 HEPAVIH)

Author

Salmon, D., Usubillaga, R., Sogni, P., Terris, B., Tremeaux, P., Katlama, C., Valantin, M.A., Stitou, H., Simon, A., Cacoub, P., Nafissa, S., Benhamou, Y., Charlotte, F., Fourati, Virologie: S., Poizot-Martin, I., Zaegel, O., Laroche, H., Tamalet, C., Pialoux, G., Chas, J., Callard, P., Bendjaballah, F., Amiel, C., Le Pendeven, C., Marchou, B., Alric, L., Barange, K., Metivier, S., Selves, J., Larroquette, F., Rosenthal, E., Infectiologie, Naqvi, A., Rio, V., Haudebourg, J., Saint-Paul, M.C., Monte, A. De, Giordanengo, V., Partouche, C., Bouchaud, O., Martin, A., Ziol, M., Baazia, Y., Iwaka-Bande, V., Gerber, A., Uzan, M., Bicart-See, A., Garipuy, D., Ferro-Collados, M.J., Virologie, Nicot, F., Gervais, A., Yazdanpanah, Y., Adle-Biassette, H., Alexandre, G., Peytavin, G., Lascoux-Combe, C., Molina, J.M., Bertheau, P., Chaix, M.L., Delaugerre, C., Maylin, S., Lacombe, K., Bottero, J., Krause, J., Girard, P.M., Wendum, D., Cervera, P., Adam, J., Viala, C., Vittecocq, D., Goujard, C., Quertainmont, Y., Teicher, E., Pallier, C., Lortholary, O., Duvivier, C., Rouzaud, C., Lourenco, J., Touam, F., Louisin, C., Avettand-Fenoel, V., Gardiennet, E., Mélard, A., Neau, D., Ochoa, A., Blanchard, E., Castet-Lafarie, S., Cazanave, C., Malvy, D., Dupon, M., Dutronc, H., Dauchy, F., Lacaze-Buzy, L., Desclaux, A., Bioulac-Sage, P., Trimoulet, P., Reigadas, S., Morlat, P., Lacoste, D., Bonnet, F., Bernard, N., Hessamfar, M., J, Paccalin, F., Martell, C., Pertusa, M.C., Vandenhende, M., Mercié, P., Pistone, T., Receveur, M.C., Méchain, M., Duffau, P., Rivoisy, C., Faure, I., Caldato, S., Bellecave, P., Tumiotto, C., Pellegrin, J.L., Viallard, J.F., Lazzaro, E., Greib, C., Zucman, D., Majerholc, C., Brollo, M., Farfour, E., Boué, F., Devoto, J. Polo, Kansau, I., Chambrin, V., Pignon, C., Berroukeche, L., Fior, R., Martinez, V., Abgrall, S., Favier, M., Deback, C., Lévy, Y., Dominguez, S., Lelièvre, J.D., Lascaux, A.S., Melica, G., Billaud, E., Raffi, F., Allavena, C., Reliquet, V., Boutoille, D., Biron, C., Lefebvre, M., Hall, N., Bouchez, S., Rodallec, A., Le Guen, L., Hemon, C., Miailhes, P., Peyramond, D., Chidiac, C., Ader, F., Biron, F., Boibieux, A., Cotte, L., Ferry, T., Perpoint, T., Koffi, J., Zoulim, F., Bailly, F., Lack, P., Maynard, M., Radenne, S., Amiri, M., Valour, F., Augustin-Normand, C., Scholtes, C., Le-Thi, T.T., Piroth, L., Chavanet, P., Duong Van Huyen, M., Buisson, M., Waldner-Combernoux, A., Mahy, S., Salmon Rousseau, A., Martins, C., Aumaître, H., Galim, S., Bani-Sadr, F., Lambert, D., Nguyen, Y., Berger, J.L., Hentzien, M., Brodard, V., Rey, D., Partisani, M., Batard, M.L., Cheneau, C., Priester, M., Bernard-Henry, C., de Mautort, E., Fischer, P., Gantner, P., Fafi-Kremer, S., Roustant, F., Platterier, P., Kmiec, I., Traore, L., Lepuil, S., Parlier, S., Sicart-Payssan, V., Bedel, E., Anriamiandrisoa, S., Pomes, C., Mole, M., Bolliot, C., Catalan, P., Mebarki, M., Adda-Lievin, A., Thilbaut, P., Ousidhoum, Y., Makhoukhi, F.Z., Braik, O., Bayoud, R., Gatey, C., Pietri, M.P., Le Baut, V., Ben Rayana, R., Bornarel, D., Chesnel, C., Beniken, D., Pauchard, M., Akel, S., Lions, C., Ivanova, A., Ritleg, A.-S., Debreux, C., Chalal, L., Zelie, J., Hue, H., Soria, A., Cavellec, M., Breau, S., Joulie, A., Fisher, P., Gohier, S., Croisier-Bertin, D., Ogoudjobi, S., Brochier, C., Thoirain-Galvan, V., Le Cam, M., Wittkop, L., Esterle, L., Izopet, J., Serfaty, L., Paradis, V., Spire, B., Carrieri, P., Zaegel-Faucher, O., Meyer, L., Boufassa, F., Autran, B., Roque, A.M., Solas, C., Fontaine, H., Costagliola, D., Petrov-Sanchez, V., Levier, A., P. Carrieri, Chalouni, M., Conte, V., Dequae-Merchadou, L., Desvallées, M., Gilbert, C., Gillet, S., Guillochon, Q., Khan, C., Knight, R., Marcellin, F., Michel, L., Mora, M., Protopopescu, C., Roux, P., Barré, T., Ramier, C., Sow, A., Di Beo, V., Bureau, M., Marcellin, Fabienne, Brégigeon-Ronot, Sylvie, Ramier, Clémence, Protopopescu, Camelia, Gilbert, Camille, Di Beo, Vincent, Duvivier, Claudine, Bureau-Stoltmann, Morgane, Rosenthal, Eric, Wittkop, Linda, Salmon-Céron, Dominique, Carrieri, Patrizia, Sogni, Philippe, and Barré, Tangui

Published
2023
Full Text
View/download PDF

2. SARS CoV-2 seroprevalence among HIV-negative participants using tenofovir/emtricitabine-based PrEP in 2020 - a sub-study of PREVENIR-ANRS and SAPRIS-Sero

Author

Delaugerre, C., Assoumou, L., Maylin, S., Minier, M., Gabassi, A., Genin, M., Beniguel, L., Ghosn, J., lamballerie, X de., Mouhebb, M El., Costagliola, D., Carrat, F., and Molina, J-M.

Subjects
Men -- Health aspects, Health
Abstract

Background: Tenofovir (TDF) has shown activity on the SARS-CoV-2 RdR polymerase in vitro and in ferrets. There is controversy regarding the potential benefit of TDF to reduce SARS-CoV-2 infection or [...]

Published
2021
Full Text
View/download PDF

3. Post‐HCV cure self‐reported changes in physical activity, eating behaviours, and fatigue in people living with HIV (ANRS CO13 HEPAVIH)

Author

Marcellin, Fabienne, Di Beo, Vincent, Esterle, Laure, Abgrall, Sophie, Pialoux, Gilles, Barré, Tangui, Wittkop, Linda, Salmon‐ceron, Dominique, Sogni, Philippe, Carrieri, Patrizia, Roustant, F, Platterier, P, Kmiec, I, Traore, L, Lepuil, S, Parlier, S, Sicart‐payssan, V, Bedel, E, Anriamiandrisoa, S, Pomes, C, Mole, M, Bolliot, C, Catalan, P, Mebarki, M, Adda‐lievin, A, Thilbaut, P, Ousidhoum, Y, Makhoukhi, F.Z, Braik, O, Bayoud, R, Gatey, C, Pietri, M.P, Le Baut, V, Ben Rayana, R, Bornarel, D, Chesnel, C, Beniken, D, Pauchard, M, Akel, S, Lions, C, Ivanova, A, Ritleg, A‐s, Debreux, C, Chalal, L, Zelie, J, Hue, H, Soria, A, Cavellec, M, Breau, S, Joulie, A, Fisher, P, Gohier, S, Croisier‐bertin, D, Ogoudjobi, S, Brochier, C, Thoirain‐galvan, V, Le Cam, M, Chalouni, M, Conte, V, Dequae‐merchadou, L, Desvallees, M, Gilbert, C, Gillet, S, Knight, R, Lemboub, T, Michel, L, Mora, M, Protopopescu, C, Roux, P, Tezkratt, S, Ramier, C, Sow, A, Bureau, M, Trimoulet, P, Izopet, J, Serfaty, L, Paradis, V, Spire, B, Valantin, V., Chas, J, Zaegel‐faucher, O, Barange, K, Naqvi, A, Rosenthal, E, Bicart‐see, A, Bouchaud, O, Gervais, A, Lascoux‐combe, C, Goujard, C, Lacombe, K, Duvivier, C, Neau, D, Morlat, P, Bani‐sadr, F, Meyer, L, Boufassa, F, Autran, B, Roque, A.M, Solas, C, Fontaine, H, Costagliola, D, Piroth, L, Simon, A, Zucman, D, Boué, F, Miailhes, P, Billaud, E, Aumaître, H, Rey, D, Peytavin, G, Petrov‐sanchez, V, Levier, A, Usubillaga, R., Terris, B, Tremeaux, P, Katlama, C, Stitou, H, Cacoub, P, Nafissa, S, Benhamou, Y, Charlotte, F, Fourati, S, Poizot‐martin, I, Zaegel, O, Laroche, H, Tamalet, C, Callard, P, Bendjaballah, F, Amiel, C, Le Pendeven, C, Marchou, B, Alric, L, Metivier, S, Selves, J, Larroquette, F, Rio, V, Haudebourg, J, Saint‐paul, M.C, de Monte, A, Giordanengo, V, Partouche, C, Martin, A, Ziol, M, Baazia, Y, Iwaka‐bande, V, Gerber, A, Uzan, M, Garipuy, D, Ferro‐collados, M.J, Nicot, F, Yazdanpanah, Y, Adle‐biassette, H, Alexandre, G, Molina, J.M, Bertheau, P, Chaix, M.L, Delaugerre, C, Maylin, S, Bottero, J, Krause, J, Girard, P.M, Wendum, D, Cervera, P, Adam, J, Viala, C, Vittecocq, D, Quertainmont, Y, Teicher, E, Pallier, C, Lortholary, O, Rouzaud, C, Lourenco, J, Touam, F, Louisin, C, Avettand‐fenoel, V, Gardiennet, E, Mélard, A, Ochoa, A, Blanchard, E, Castet‐lafarie, S, Cazanave, C, Malvy, D, Dupon, M, Dutronc, H, Dauchy, F, Lacaze‐buzy, L, Desclaux, A, Bioulac‐sage, P, Reigadas, S, Lacoste, D, Bonnet, F, Bernard, N, Hessamfar, M, Paccalin, J.F, Martell, C, Pertusa, M.C, Vandenhende, M, Mercié, P, Pistone, T, Receveur, M.C, Méchain, M, Duffau, P, Rivoisy, C, Faure, I, Caldato, S, Bellecave, P, Tumiotto, C, Pellegrin, J.L, Viallard, J.F, Lazzaro, E, Greib, C, Majerholc, C, Brollo, M, Farfour, E, Polo Devoto, J, Kansau, I, Chambrin, V, Pignon, C, Berroukeche, L, Fior, R, Martinez, V, Favier, M, Deback, C, Lévy, Y, Dominguez, S, Lelièvre, J.D, Lascaux, A.S, Melica, G, Raffi, F, Allavena, C, Reliquet, V, Boutoille, D, Biron, C, Lefebvre, M, Hall, N, Bouchez, S, Rodallec, A, Le Guen, L, Hemon, C, Peyramond, D, Chidiac, C, Ader, F, Biron, F, Boibieux, A, Cotte, L, Ferry, T, Perpoint, T, Koffi, J, Zoulim, F, Bailly, F, Lack, P, Maynard, M, Radenne, S, Amiri, M, Valour, F, Augustin‐normand, C, Scholtes, C, Le‐thi, T.T, Chavanet, P, Duong van Huyen, M, Buisson, M, Waldner‐combernoux, A, Mahy, S, Salmon Rousseau, A, Martins, C, Galim, S, Lambert, D, Nguyen, Y, Berger, J.L, Hentzien, M, Brodard, V, Partisani, M, Batard, M.L, Cheneau, C, Priester, M, Bernard‐henry, C, de Mautort, E, Fischer, P, Gantner, P, Fafi‐kremer, S, Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U1252 INSERM - Aix Marseille Univ - UMR 259 IRD), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut des sciences de la santé publique [Marseille] (ISSPAM), Team MORPH3EUS (INSERM U1219 - UB - ISPED), Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), CIC Bordeaux, Université Bordeaux Segalen - Bordeaux 2-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, AP-HP - Hôpital Antoine Béclère [Clamart], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CHU Tenon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), CHU Bordeaux [Bordeaux], Hôpital Cochin [AP-HP], Université Paris Descartes - Paris 5 (UPD5), Physiopathologie du système immunitaire (Inserm U1223), Institut Pasteur [Paris] (IP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), ANRS CO13 HEPAVIH Study Group: F Roustant, P Platterier, I Kmiec, L Traore, S Lepuil, S Parlier, V Sicart-Payssan, E Bedel, S Anriamiandrisoa, C Pomes, M Mole, C Bolliot, P Catalan, M Mebarki, A Adda-Lievin, P Thilbaut, Y Ousidhoum, F Z Makhoukhi, O Braik, R Bayoud, C Gatey, M P Pietri, V Le Baut, R Ben Rayana, D Bornarel, C Chesnel, D Beniken, M Pauchard, S Akel, C Lions, A Ivanova, A-S Ritleg, C Debreux, L Chalal, J Zelie, H Hue, A Soria, M Cavellec, S Breau, A Joulie, P Fisher, S Gohier, D Croisier-Bertin, S Ogoudjobi, C Brochier, V Thoirain-Galvan, M Le Cam, M Chalouni, V Conte, L Dequae-Merchadou, M Desvallees, C Gilbert, S Gillet, R Knight, T Lemboub, L Michel, M Mora, C Protopopescu, P Roux, S Tezkratt, C Ramier, A Sow, M Bureau, P Trimoulet, J Izopet, L Serfaty, V Paradis, B Spire, Valantin, J Chas, O Zaegel-Faucher, K Barange, A Naqvi, E Rosenthal, A Bicart-See, O Bouchaud, A Gervais, C Lascoux-Combe, C Goujard, K Lacombe, C Duvivier, D Neau, P Morlat, F Bani-Sadr, L Meyer, F Boufassa, B Autran, A M Roque, C Solas, H Fontaine, D Costagliola, L Piroth, A Simon, D Zucman, F Boué, P Miailhes, E Billaud, H Aumaître, D Rey, G Peytavin, V Petrov-Sanchez, A Levier, R Usubillaga, B Terris, P Tremeaux, C Katlama, H Stitou, P Cacoub, S Nafissa, Y Benhamou, F Charlotte, S Fourati, I Poizot-Martin, O Zaegel, H Laroche, C Tamalet, P Callard, F Bendjaballah, C Amiel, C Le Pendeven, B Marchou, L Alric, S Metivier, J Selves, F Larroquette, V Rio, J Haudebourg, M C Saint-Paul, A De Monte, V Giordanengo, C Partouche, A Martin, M Ziol, Y Baazia, V Iwaka-Bande, A Gerber, M Uzan, D Garipuy, M J Ferro-Collados, J Selves, F Nicot, Y Yazdanpanah, H Adle-Biassette, G Alexandre, J M Molina, P Bertheau, M L Chaix, C Delaugerre, S Maylin, J Bottero, J Krause, P M Girard, D Wendum, P Cervera, J Adam, C Viala, D Vittecocq, Y Quertainmont, E Teicher, C Pallier, O Lortholary, C Rouzaud, J Lourenco, F Touam, C Louisin, V Avettand-Fenoel, E Gardiennet, A Mélard, A Ochoa, E Blanchard, S Castet-Lafarie, C Cazanave, D Malvy, M Dupon, H Dutronc, F Dauchy, L Lacaze-Buzy, A Desclaux, P Bioulac-Sage, S Reigadas, D Lacoste, F Bonnet, N Bernard, M Hessamfar, J F Paccalin, C Martell, M C Pertusa, M Vandenhende, P Mercié, D Malvy, T Pistone, M C Receveur, M Méchain, P Duffau, C Rivoisy, I Faure, S Caldato, P Bioulac-Sage, S Reigadas, P Bellecave, C Tumiotto, J L Pellegrin, J F Viallard, E Lazzaro, C Greib, P Bioulac-Sage, S Reigadas, C Majerholc, M Brollo, E Farfour, J Polo Devoto, I Kansau, V Chambrin, C Pignon, L Berroukeche, R Fior, V Martinez, M Favier, C Deback, Y Lévy, S Dominguez, J D Lelièvre, A S Lascaux, G Melica, F Raffi, C Allavena, V Reliquet, D Boutoille, C Biron, M Lefebvre, N Hall, S Bouchez, A Rodallec, L Le Guen, C Hemon, D Peyramond, C Chidiac, F Ader, F Biron, A Boibieux, L Cotte, T Ferry, T Perpoint, J Koffi, F Zoulim, F Bailly, P Lack, M Maynard, S Radenne, M Amiri, F Valour, J Koffi, F Zoulim, F Bailly, P Lack, M Maynard, S Radenne, C Augustin-Normand, C Scholtes, T T Le-Thi, P Chavanet, M Duong Van Huyen, M Buisson, A Waldner-Combernoux, S Mahy, A Salmon Rousseau, C Martins, S Galim, D Lambert, Y Nguyen, J L Berger, M Hentzien, V Brodard, M Partisani, M L Batard, C Cheneau, M Priester, C Bernard-Henry, E de Mautort, P Fischer, P Gantner, S Fafi-Kremer, Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Pasteur [Paris], Statistics In System biology and Translational Medicine (SISTM), Inria Bordeaux - Sud-Ouest, Institut National de Recherche en Informatique et en Automatique (Inria)-Institut National de Recherche en Informatique et en Automatique (Inria)- Bordeaux population health (BPH), and Malbec, Odile

Subjects
0303 health sciences, Hepatology, business.industry, [SDV]Life Sciences [q-bio], Human immunodeficiency virus (HIV), MEDLINE, Physical activity, medicine.disease_cause, 3. Good health, [SDV] Life Sciences [q-bio], 03 medical and health sciences, 0302 clinical medicine, Infectious Diseases, Virology, Medicine, 030211 gastroenterology & hepatology, business, Eating behaviour, ComputingMilieux_MISCELLANEOUS, 030304 developmental biology, Clinical psychology
Abstract

International audience; No abstract available

Published
2021

6. Insulin resistance and geographical origin: major predictors of liver fibrosis and response to peginterferon and ribavirin in HCV-4

Author

Moucari, R., Ripault, M.-P., Martinot-Peignoux, M., Voitot, H., Cardoso, A.-C., Stern, C., Boyer, N., Maylin, S., Nicolas-Chanoine, M.-H., Vidaud, M., Valla, D., Bedossa, P., and Marcellin, P.

Subjects
Hepatitis C -- Care and treatment, Hepatitis C -- Patient outcomes, Hepatitis C -- Models, Hepatitis C -- Research, Insulin resistance -- Research, Peginterferon alfa-2a -- Dosage and administration, Peginterferon alfa-2a -- Research, Peginterferon alfa-2b -- Dosage and administration, Peginterferon alfa-2b -- Research, Ribavirin -- Dosage and administration, Ribavirin -- Research, Health
Published
2009

8. Surfaces and equipment contamination by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the emergency department at a university hospital

Author

Peyrony, Olivier, primary, Ellouze, Sami, additional, Fontaine, Jean-Paul, additional, Thegat-Le Cam, Micheline, additional, Salmona, Maud, additional, Feghoul, Linda, additional, Mahjoub, Nadia, additional, Mercier-Delarue, Séverine, additional, Gabassi, Audrey, additional, Delaugerre, Constance, additional, Le Goff, Jérôme, additional, Achili, Y., additional, Ades, L., additional, Aguinaga, L., additional, Archer, G., additional, Benattia, A., additional, Bercot, B., additional, Bergeron, A., additional, Bertinchamp, R., additional, Bondeelle, L., additional, Bouaziz, J.D., additional, Bouda, D., additional, Boutboul, D., additional, Brindel Berthon, I., additional, Brugnet, E., additional, Caillat Zucman, S., additional, Cassonnet, S., additional, Celli Lebras, K., additional, Chabert, J., additional, Chaix, M.L., additional, Chevret, S., additional, Clément, M., additional, Davoine, C., additional, De Castro, N., additional, De Kerviler, E., additional, De Margerie-Mellon, C., additional, Depret, F., additional, Denis, B., additional, Djaghout, L., additional, Dupin, C., additional, Farge-Blancel, D., additional, Fauvaux, C., additional, Fenaux, H., additional, Feredj, E., additional, Feyeux, D., additional, Fremeaux-Bacchi, V., additional, Galicier, L., additional, Garestier, J., additional, Harel, S., additional, Jegu, A.L., additional, Kozakiewicz, E., additional, Lebel M Baye, A., additional, Le Guen, P., additional, Lengline, E., additional, Liegeon, G., additional, Lorillon, G., additional, Madelaine Chambrin, I., additional, Martin de Frémont, G., additional, Maylin, S., additional, Mehlman, C., additional, Meunier, M., additional, Molina, J.M., additional, Morin, F., additional, Oksenhendler, E., additional, Peffault de la Tour, R., additional, Plaud, B., additional, Rouveau, M., additional, Saussereau, J., additional, Schnepf, N., additional, Soret, J., additional, Tazi, A., additional, and Tremorin, M.T., additional

Published
2020
Full Text
View/download PDF

9. Patient-reported symptoms during direct-acting antiviral treatment: A real-life study in HIV-HCV coinfected patients (ANRS CO13 HEPAVIH)

Author

Marcellin, Fabienne, primary, Di Beo, Vincent, additional, Aumaitre, Hugues, additional, Mora, Marion, additional, Wittkop, Linda, additional, Duvivier, Claudine, additional, Protopopescu, Camelia, additional, Lacombe, Karine, additional, Esterle, Laure, additional, Berenger, Cyril, additional, Gilbert, Camille, additional, Bouchaud, Olivier, additional, Poizot-Martin, Isabelle, additional, Sogni, Philippe, additional, Salmon-Ceron, Dominique, additional, Carrieri, Patrizia, additional, Salmon, D., additional, Wittkop, L., additional, Sogni, P., additional, Esterle, L., additional, Trimoulet, P., additional, Izopet, J., additional, Serfaty, L., additional, Paradis, V., additional, Spire, B., additional, Carrieri, P., additional, Valantin, M.A., additional, Pialoux, G., additional, Chas, J., additional, Poizot-Martin, I., additional, Barange, K., additional, Naqvi, A., additional, Rosenthal, E., additional, Bicart-See, A., additional, Bouchaud, O., additional, Gervais, A., additional, Lascoux-Combe, C., additional, Goujard, C., additional, Lacombe, K., additional, Duvivier, C., additional, Neau, D., additional, Morlat, P., additional, Bani-Sadr, F., additional, Meyer, L., additional, Boufassa, F., additional, Autran, B., additional, Roque, A.M., additional, Solas, C., additional, Fontaine, H., additional, Costagliola, D., additional, Piroth, L., additional, Simon, A., additional, Zucman, D., additional, Boué, F., additional, Miailhes, P., additional, Billaud, E., additional, Aumaître, H., additional, Rey, D., additional, Peytavin, G., additional, Petrov-Sanchez, V., additional, Lebrasseur-Longuet, D., additional, Usubillaga, R., additional, Terris, B., additional, Tremeaux, P., additional, Katlama, C., additional, Stitou, H., additional, Cacoub, P., additional, Nafissa, S., additional, Benhamou, Y., additional, Charlotte, F., additional, Fourati, S., additional, Zaegel, O., additional, Laroche, H., additional, Tamalet, C., additional, Callard, P., additional, Bendjaballah, F., additional, Amiel, C., additional, Le Pendeven, C., additional, Marchou, B., additional, Alric, L., additional, Metivier, S., additional, Selves, J., additional, Larroquette, F., additional, Rio, V., additional, Haudebourg, J., additional, Saint-Paul, M.C., additional, De Monte, A., additional, Giordanengo, V., additional, Partouche, C., additional, Martin, A., additional, Ziol, M., additional, Baazia, Y., additional, Iwaka-Bande, V., additional, Gerber, A., additional, Uzan, M., additional, Garipuy, D., additional, Ferro-Collados, M.J., additional, Nicot, F., additional, Yazdanpanah, Y., additional, Adle-Biassette, H., additional, Alexandre, G., additional, Molina, J.M., additional, Bertheau, P., additional, Chaix, M.L., additional, Delaugerre, C., additional, Maylin, S., additional, Bottero, J., additional, Krause, J., additional, Girard, P.M., additional, Wendum, D., additional, Cervera, P., additional, Adam, J., additional, Viala, C., additional, Vittecocq, D., additional, Quertainmont, Y., additional, Teicher, E., additional, Pallier, C., additional, Lortholary, O., additional, Rouzaud, C., additional, Lourenco, J., additional, Touam, F., additional, Louisin, C., additional, Avettand-Fenoel, V., additional, Gardiennet, E., additional, Mélard, A., additional, Ochoa, A., additional, Blanchard, E., additional, Castet-Lafarie, S., additional, Cazanave, C., additional, Malvy, D., additional, Dupon, M., additional, Dutronc, H., additional, Dauchy, F., additional, Lacaze-Buzy, L., additional, Desclaux, A., additional, Bioulac-Sage, P., additional, Reigadas, S., additional, Lacoste, D., additional, Bonnet, F., additional, Bernard, N., additional, Hessamfar, J, M., additional, Paccalin, F., additional, Martell, C., additional, Pertusa, M.C., additional, Vandenhende, M., additional, Mercié, P., additional, Pistone, T., additional, Receveur, M.C., additional, Méchain, M., additional, Duau, P., additional, Rivoisy, C., additional, Faure, I., additional, Caldato, S., additional, Bellecave, P., additional, Tumiotto, C., additional, Pellegrin, J.L., additional, Viallard, J.F., additional, Lazzaro, E., additional, Greib, C., additional, Majerholc, C., additional, Brollo, M., additional, Farfour, E., additional, Polo Devoto, J., additional, Kansau, I., additional, Chambrin, V., additional, Pignon, C., additional, Berroukeche, L., additional, Fior, R., additional, Martinez, V., additional, Abgrall, S., additional, Favier, M., additional, Deback, C., additional, Lévy, Y., additional, Dominguez, S., additional, Lelièvre, J.D., additional, Lascaux, A.S., additional, Melica, G., additional, Raffi, F., additional, Allavena, C., additional, Reliquet, V., additional, Boutoille, D., additional, Biron, C., additional, Lefebvre, M., additional, Hall, N., additional, Bouchez, S., additional, Rodallec, A., additional, Le Guen, L., additional, Hemon, C., additional, Peyramond, D., additional, Chidiac, C., additional, Ader, F., additional, Biron, F., additional, Boibieux, A., additional, Cotte, L., additional, Ferry, T., additional, Perpoint, T., additional, Koffi, J., additional, Zoulim, F., additional, Bailly, F., additional, Lack, P., additional, Maynard, M., additional, Radenne, S., additional, Amiri, M., additional, Valour, F., additional, Augustin-Normand, C., additional, Scholtes, C., additional, Le-Thi, T.T., additional, Chavanet, P., additional, Duong Van Huyen, M., additional, Buisson, M., additional, Waldner-Combernoux, A., additional, Mahy, S., additional, Binois, R., additional, Simonet-Lann, A.L., additional, Croisier-Bertin, D., additional, Salmon Rousseau, A., additional, Martins, C., additional, Galim, S., additional, Lambert, D., additional, Nguyen, Y., additional, Berger, J.L., additional, Hentzien, M., additional, Brodard, V., additional, Partisani, M., additional, Batard, M.L., additional, Cheneau, C., additional, Priester, M., additional, Bernard-Henry, C., additional, de Mautort, E., additional, Gantner et S Fafi-Kremer, P., additional, Roustant, F., additional, Platterier, P., additional, Kmiec, I., additional, Traore, L., additional, Lepuil, S., additional, Parlier, S., additional, Sicart-Payssan, V., additional, Bedel, E., additional, Anriamiandrisoa, S., additional, Pomes, C., additional, Mole, M., additional, Bolliot, C., additional, Catalan, P., additional, Mebarki, M., additional, Adda-Lievin, A., additional, Thilbaut, P., additional, Ousidhoum, Y., additional, Makhoukhi, F.Z., additional, Braik, O., additional, Bayoud, R., additional, Gatey, C., additional, Pietri, M.P., additional, Le Baut, V., additional, Ben Rayana, R., additional, Bornarel, D., additional, Chesnel, C., additional, Beniken, D., additional, Pauchard, M., additional, Akel, S., additional, Lions, C., additional, Ivanova, A., additional, Ritleg, A.-S., additional, Debreux, C., additional, Chalal, L., additional, Zelie, J., additional, Hue, H., additional, Soria, A., additional, Cavellec, M., additional, Breau, S., additional, Joulie, A., additional, Fisher, P., additional, Gohier, S., additional, Ogoudjobi, S., additional, Brochier, C., additional, Thoirain-Galvan, V., additional, Le Cam, M., additional, Chalouni, M., additional, Conte, V., additional, Dequae-Merchadou, L., additional, Desvallees, M., additional, Gilbert, C., additional, Gillet, S., additional, Knight, R., additional, Lemboub, T., additional, Marcellin, F., additional, Michel, L., additional, Mora, M., additional, Protopopescu, C., additional, Roux, P., additional, Tezkratt, S., additional, Barré, T., additional, Baudoin, M., additional, Santos, M., additional, Di Beo, V., additional, and Nishimwe, M., additional

Published
2020
Full Text
View/download PDF

10. Transactions of the Royal Society of Tropical Medicine and Hygiene

Author

Boyd, A., KOUAME, M. G., HOUGHTALING, L., Moh, R., Gabillard, Delphine, Maylin, S., CHEKARAOU, M. A., Delaugerre, C., Anglaret, Xavier, EHOLIE, S. P., Danel, Christine, Zoulim, F., Lacombe, K., Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), and Agence Nationale de Recherches sur le Sida et les Hépatites Virales

Subjects
IDLIC, virus diseases, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, digestive system diseases
Abstract

Background In human immunodeficiency virus (HIV) and hepatitis B virus (HBV) co-infected patients from sub-Saharan Africa with hepatitis B e antigen (HBeAg)-negative status, data are limited on the evolution of HBV activity when antiretroviral treatment (ART) is absent. Methods A total of 43 HBeAg-negative co-infected patients not indicated for ART (per concomitant World Health Organization recommendations) were followed during participation in a randomized controlled trial in Cote d'Ivoire. Chronic HBeAg-negative phases were classified at yearly visits and defined as infection' (HBV DNA 10 000 copies/mL and/or above normal ALT). Dispersion in HBV DNA and ALT levels during follow-up was assessed using interquartile range (IQR) regression. Results During a median 25 months (IQR 19-31), 17 (40%) patients consistently had infection', 5 (12%) consistently had hepatitis' and 21 (48%) fluctuated between phases. Wider dispersion in HBV DNA over time was associated with higher baseline HIV RNA (p=0.02) and higher baseline HBV DNA levels (p=0.008), while wider dispersion in ALT was associated with higher baseline HIV RNA (p4.0 log(10) IU/mL (p=0.02). Conclusions HBV activity is common with HBeAg-negative status, whose variation is partly linked to HIV replication. Fluctuations in disease phase make it difficult to assess the risk of morbidity and mortality after ART initiation.

Published
2019

11. Immune-escape mutations and stop-codons in HBsAg develop in a large proportion of patients with chronic HBV infection exposed to anti-HBV drugs in Europe

Author

Colagrossi, L. Hermans, L.E. Salpini, R. Di Carlo, D. Pas, S.D. Alvarez, M. Ben-Ari, Z. Boland, G. Bruzzone, B. Coppola, N. Seguin-Devaux, C. Dyda, T. Garcia, F. Kaiser, R. Köse, S. Krarup, H. Lazarevic, I. Lunar, M.M. Maylin, S. Micheli, V. Mor, O. Paraschiv, S. Paraskevis, D. Poljak, M. Puchhammer-Stöckl, E. Simon, F. Stanojevic, M. Stene-Johansen, K. Tihic, N. Trimoulet, P. Verheyen, J. Vince, A. Lepej, S.Z. Weis, N. Yalcinkaya, T. Boucher, C.A.B. Wensing, A.M.J. Perno, C.F. Svicher, V. HEPVIR working group of the European Society for translational antiviral research (ESAR)

Abstract

Background: HBsAg immune-escape mutations can favor HBV-transmission also in vaccinated individuals, promote immunosuppression-driven HBV-reactivation, and increase fitness of drug-resistant strains. Stop-codons can enhance HBV oncogenic-properties. Furthermore, as a consequence of the overlapping structure of HBV genome, some immune-escape mutations or stop-codons in HBsAg can derive from drug-resistance mutations in RT. This study is aimed at gaining insight in prevalence and characteristics of immune-associated escape mutations, and stop-codons in HBsAg in chronically HBV-infected patients experiencing nucleos(t)ide analogues (NA) in Europe. Methods: This study analyzed 828 chronically HBV-infected European patients exposed to ≥ 1 NA, with detectable HBV-DNA and with an available HBsAg-sequence. The immune-associated escape mutations and the NA-induced immune-escape mutations sI195M, sI196S, and sE164D (resulting from drug-resistance mutation rtM204 V, rtM204I, and rtV173L) were retrieved from literature and examined. Mutations were defined as an aminoacid substitution with respect to a genotype A or D reference sequence. Results: At least one immune-associated escape mutation was detected in 22.1% of patients with rising temporal-trend. By multivariable-analysis, genotype-D correlated with higher selection of ≥ 1 immune-associated escape mutation (OR[95%CI]:2.20[1.32-3.67], P = 0.002). In genotype-D, the presence of ≥ 1 immune-associated escape mutations was significantly higher in drug-exposed patients with drug-resistant strains than with wild-type virus (29.5% vs 20.3% P = 0.012). Result confirmed by analysing drug-naïve patients (29.5% vs 21.2%, P = 0.032). Strong correlation was observed between sP120T and rtM204I/V (P < 0.001), and their co-presence determined an increased HBV-DNA. At least one NA-induced immune-escape mutation occurred in 28.6% of patients, and their selection correlated with genotype-A (OR[95%CI]:2.03[1.32-3.10],P = 0.001). Finally, stop-codons are present in 8.4% of patients also at HBsAg-positions 172 and 182, described to enhance viral oncogenic-properties. Conclusions: Immune-escape mutations and stop-codons develop in a large fraction of NA-exposed patients from Europe. This may represent a potential threat for horizontal and vertical HBV transmission also to vaccinated persons, and fuel drug-resistance emergence. © 2018 The Author(s).

Published
2018

12. Higher Mortality Despite Early Antiretroviral Therapy in Human Immunodeficiency Virus and Hepatitis B Virus (HBV)-Coinfected Patients With High HBV Replication

Author

KOUAME, Menan Gerard, Boyd, A., Moh, Raoul, Badje, Anani dodzi, Gabillard, Delphine, OUATTARA, Eric, N'Takpe, Jean-Baptiste, EMIEME, A., Maylin, S., CHEKARAOU, M. A., Eholie, Serge Paul, Zoulim, F., Lacombe, K., Anglaret, Xavier, Danel, Christine, Bordeaux population health (BPH), and Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
IDLIC, virus diseases, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, PACCI
Abstract

Background: In HIV-infected patients, hepatitis B virus (HBV)-coinfection increases the risk of disease progression. Tenofovir+emtricitabine/lamivudine (TDF/XTC)-based antiretroviral therapy (ART), which suppresses HIV and HBV replication, has the potential for decreasing this risk. Here, we analyze the association between HBV replication, early-ART, and mortality in West-African adults. Methods: The Temprano randomized-control trial assessed the benefits of immediately initiating versus deferring ART in HIV-infected adults with high CD4 counts. After trial completion, participants continued follow-up in a post-trial phase. We analyzed the association between HBV-status, immediate-ART, and mortality over the entire trial and post-trial follow-up using multivariable Cox proportional hazards regression. Results: 2052 HIV-infected adults (median baseline CD4=464/mm3) were followed for 9394 person-years. At baseline, 1862 (91%) were HIV-monoinfected and 190 (9%) HIV-HBV-coinfected. Of the latter, 135 (71%) had plasma HBV-DNA /=2000 IU/ml. The 60-month probability of death was 11.8% (95%CI=5.4-24.5) in coinfected patients with HBV-DNA >/=2000 IU/ml, 4.4% (95%CI=1.9-10.4) in coinfected patients with HBV-DNA /=2000 IU/ml and 0.90 (95%CI=0.36-2.24) in coinfected patients with HBV-DNA

Published
2018

13. Hepatitis C subtype distribution in chronically infected patients with mild liver fibrosis in France: the GEMHEP study

Author

Semenova, T., primary, Nemoz, B., additional, Thibault, V., additional, Lagathu, G., additional, Duverlie, G., additional, Brochot, E., additional, Trimoulet, P., additional, Payan, C., additional, Vallet, S., additional, Henquell, C., additional, Chevaliez, S., additional, Bouvier-Alias, M., additional, Maylin, S., additional, Roque-Afonso, A-M., additional, Izquierdo, L., additional, Lunel-Fabiani, F., additional, Marcellin, P., additional, Morand, P., additional, Leroy, V., additional, and Larrat, S., additional

Published
2019
Full Text
View/download PDF

14. Immune-escape mutations and stop-codons in HBsAg develop in a large proportion of patients with chronic HBV infection exposed to anti-HBV drugs in Europe

Author

Colagrossi, L. (Luna), Hermans, L.E. (Lucas Etienne), Salpini, R. (Romina), Di Carlo, D., Pas, S.D. (Suzan), Alvarez, M.R. (Marta), Ben Ari, Z. (Ziv), Boland, G.J. (Greet), Bruzzone, B. (Bianca), Coppola, N. (Nicola), Seguin-Devaux, C., Dyda, T. (Tomasz), Garcia, F. (Federico), Kaiser, R. (Rolf), Köse, S. (Sukran), Krarup, H.B. (H.), Lazarevic, I. (Ivana), Lunar, M.M. (Maja M.), Maylin, S. (Sarah), Micheli, V. (Valeria), Mor, O. (Orna), Paraschiv, C. (Corina), Paraskevis, D. (Dimitrios), Poljak, M. (Mario), Puchhammer-Stöckl, E. (Elisabeth), Simon, F. (François), Stanojevic, M. (Maja), Stene-Johansen, K. (Kathrine), Tihic, N. (Nijaz), Trimoulet, P. (Pascale), Verheyen, J. (Jens), Vince, A. (Adriana), Lepej, S.Z. (Snjezana), Weis, N. (Nina), Yalcinkaya, T. (Tülay), Boucher, C.A.B. (Charles), Wensing, A. (Amj), Perno, C.F. (Carlo), Svicher, V. (Valentina), Colagrossi, L. (Luna), Hermans, L.E. (Lucas Etienne), Salpini, R. (Romina), Di Carlo, D., Pas, S.D. (Suzan), Alvarez, M.R. (Marta), Ben Ari, Z. (Ziv), Boland, G.J. (Greet), Bruzzone, B. (Bianca), Coppola, N. (Nicola), Seguin-Devaux, C., Dyda, T. (Tomasz), Garcia, F. (Federico), Kaiser, R. (Rolf), Köse, S. (Sukran), Krarup, H.B. (H.), Lazarevic, I. (Ivana), Lunar, M.M. (Maja M.), Maylin, S. (Sarah), Micheli, V. (Valeria), Mor, O. (Orna), Paraschiv, C. (Corina), Paraskevis, D. (Dimitrios), Poljak, M. (Mario), Puchhammer-Stöckl, E. (Elisabeth), Simon, F. (François), Stanojevic, M. (Maja), Stene-Johansen, K. (Kathrine), Tihic, N. (Nijaz), Trimoulet, P. (Pascale), Verheyen, J. (Jens), Vince, A. (Adriana), Lepej, S.Z. (Snjezana), Weis, N. (Nina), Yalcinkaya, T. (Tülay), Boucher, C.A.B. (Charles), Wensing, A. (Amj), Perno, C.F. (Carlo), and Svicher, V. (Valentina)

Abstract

Background: HBsAg immune-escape mutations can favor HBV-transmission also in vaccinated individuals, promote immunosuppression-driven HBV-reactivation, and increase fitness of drug-resistant strains. Stop-codons can enhance HBV oncogenic-properties. Furthermore, as a consequence of the overlapping structure of HBV genome, some immune-escape mutations or stop-codons in HBsAg can derive from drug-resistance mutations in RT. This study is aimed at gaining insight in prevalence and characteristics of immune-associated escape mutations, and stop-codons in HBsAg in chronically HBV-infected patients experiencing nucleos(t)ide analogues (NA) in Europe. Methods: This study analyzed 828 chronically HBV-infected European patients exposed to ≥ 1 NA, with detectable HBV-DNA and with an available HBsAg-sequence. The immune-associated escape mutations and the NA-induced immune-escape mutations sI195M, sI196S, and sE164D (resulting from drug-resistance mutation rtM204 V, rtM204I, and rtV173L) were retrieved from literature and examined. Mutations were defined as an aminoacid substitution with respect to a genotype A or D reference sequence. Results: At least one immune-associated escape mutation was detected in 22.1% of patients with rising temporal-trend. By multivariable-analysis, genotype-D correlated with higher selection of ≥ 1 immune-associated escape mutation (OR[95%CI]:2.20[1.32-3.67], P = 0.002). In genotype-D, the presence of ≥ 1 immune-associated escape mutations was significantly higher in drug-exposed patients with drug-resistant strains than with wild-type virus (29.5% vs 20.3% P = 0.012). Result confirmed by anal

Published
2018
Full Text
View/download PDF

15. Immune-escape mutations and stop-codons in HBsAg develop in a large proportion of patients with chronic HBV infection exposed to anti-HBV drugs in Europe

Author

Colagrossi, L, Hermans, Lucas, Salpini, R, Di Carlo, D, Pas, Suzan, Alvarez, M, Ben-Ari, Z, Boland, G, Bruzzone, B, Coppola, N, Seguin-Devaux, C, Dyda, T, Garcia, F, Kaiser, R, Kose, S, Krarup, H, Lazarevic, I, Lunar, MM, Maylin, S, Micheli, V, Mor, O, Paraschiv, S, Paraskevis, D, Poljak, M, Puchhammer-Stockl, E, Simon, F, Stanojevic, M, Stene-Johansen, K, Tihic, N, Trimoulet, P, Verheyen, J, Vince, A, Lepej, SZ, Weis, N, Yalcinkaya, T, Boucher, Charles, Wensing, AMJ, Perno, CF, Svicher, V, Colagrossi, L, Hermans, Lucas, Salpini, R, Di Carlo, D, Pas, Suzan, Alvarez, M, Ben-Ari, Z, Boland, G, Bruzzone, B, Coppola, N, Seguin-Devaux, C, Dyda, T, Garcia, F, Kaiser, R, Kose, S, Krarup, H, Lazarevic, I, Lunar, MM, Maylin, S, Micheli, V, Mor, O, Paraschiv, S, Paraskevis, D, Poljak, M, Puchhammer-Stockl, E, Simon, F, Stanojevic, M, Stene-Johansen, K, Tihic, N, Trimoulet, P, Verheyen, J, Vince, A, Lepej, SZ, Weis, N, Yalcinkaya, T, Boucher, Charles, Wensing, AMJ, Perno, CF, and Svicher, V

Published
2018

16. Genetic signatures specifically clustered in immune active HBsAg regions correlate with immunosuppression-driven HBV reactivation: an extensive analysis of HBV genome

Author

Svicher, V, Salpini, R, Colagrossi, L, Battisti, A, Bellocchi, M, Alteri, C, Armenia, D, Di Santo, F, Carioti, L, Pollicita, M, Ricciardi, A, Lichtner, M, Mastroianni, C, Paoloni, M, Marignani, M, Maylin, S, Delaugerre, C, Morisco, F, Coppola, N, Marrone, A, Di Paolo, D, Sarrecchia, C, Sarmati, L, Andreoni, M, Angelico, M, Perno, C, Svicher, V, Salpini, R, Colagrossi, L, Battisti, A, Bellocchi, Mc, Alteri, C, Armenia, D, Di Santo, F, Carioti, L, Pollicita, M, Ricciardi, A, Lichtner, M, Mastroianni, C, Paoloni, M, Marignani, M, Maylin, S, Delaugerre, C, Morisco, F, Coppola, N, Marrone, A, Di Paolo, D, Sarrecchia, C, Sarmati, L, Andreoni, M, Angelico, M, and Perno, Cf

Subjects
Settore MED/07
Published
2015

17. A hyper-glycosilation of HBV surface major hydrophilic correlates with immunosuppression-driven HBV reactivation and hampers HBsAg recognition in vitro

Author

Colagrossi L, Salpini R, Surdo M, Battisti A, Pollicita M, Bertoli A, Di Santo F, Becker C, Mastroianni C, Marignani M, Maylin S, Delaugerre C, Morisco F, Coppola N, Marrone A, Sarmati L, Andreoni M, Angelico M, Verheyen J, Perno CF, Svicher V., Colagrossi, L, Salpini, R, Surdo, M, Battisti, A, Pollicita, M, Bertoli, A, Di Santo, F, Becker, C, Mastroianni, C, Marignani, M, Maylin, S, Delaugerre, C, Morisco, F, Coppola, N, Marrone, A, Sarmati, L, Andreoni, M, Angelico, M, Verheyen, J, Perno, Cf, and Svicher, V.

Published
2015

18. A hyper-glycosylation of HBV surface antigen characterizes immunosuppression-driven HBV reactivation and hinders HBsAg recognition in vitro

Author

Salpini, R., primary, Piermatteo, L., additional, Battisti, A., additional, Colagrossi, L., additional, Aragri, M., additional, Fabeni, L., additional, Bertoli, A., additional, Mastroianni, C.M., additional, Marignani, M., additional, Maylin, S., additional, Delaugerre, C., additional, Morisco, F., additional, Nicola, C., additional, Marrone, A., additional, Iapadre, N., additional, Mario, A., additional, Sarmati, L., additional, Andreoni, M., additional, Verheyen, J., additional, Silberstein, F.C., additional, Levrero, M., additional, Perno, C.F., additional, Belloni, L., additional, and Svicher, V., additional

Published
2018
Full Text
View/download PDF

19. First NGS full genome characterization of a hepatitis C virus genotype 7 divergent subtype

Author

Salmona, M, Caporossi, A, Simmonds, P, Thélu, M, Fusillier, K, Mercier-Delarue, S, De Castro, N, LeGoff, J, Chaix, M, François, O, Simon, F, Morand, P, Larrat, S, and Maylin, S

Abstract

We report the near full length genome sequence, of an hepatitis C virus isolate from a man originating from Democratic Republic of Congo, whose genotype could not be determined by the routinely used sequence technique.The near-complete genome sequence of this variant BAK1 was obtained by the association of two next generation sequencing technologies.Evolutionary analysis indicates that this isolate BAK1 could be the first reported strain belonging to a new HCV-7b subtype. This new subtype has been incorrectly identified as genotype 2 by Versant HCV Genotype 2.0 assay (LiPA).The requirement of three independent isolates has been filled and a new subtype can be assigned. More examples of HCV-7 are required to better understand its origin, its pathogenicity and its relationship with genotype 2.

Published
2016

20. IMMUNE-ESCAPE MUTATIONS AND STOP-CODONS IN HBSAG CIRCULATES IN A RELEVANT PROPORTION OF PATIENTS WITH CHRONIC HBV INFECTION EXPOSED TO ANTI-HBV DRUGS IN EUROPE: IMPLICATIONS FOR HBV TRANSMISSION IN THE SETTING OF VACCINATION AND DISEASE PROGRESSION

Author

Colagrossi, L. Hermans, L. E. Salpini, R. Pas, S. D. and Alvarez, M. Ben Ari, Z. Boland, G. Bruzzone, B. Coppola, N. Seguin-Devaux, C. Dyda, T. Garcia, F. Kaiser, R. and Kose, S. Krarup, H. Lazarevic, I. Lunar, M. M. Maylin, S. Micheli, V. Mor, O. Paraschiv, S. Paraskevis, D. and Poljak, M. Puchhammer-Stoeckl, E. Simon, F. Stanojevic, M. and Stene-Johansen, K. Tihic, N. Trimoulet, P. Verheyen, J. and Vince, A. Weis, N. Yalcinkaya, T. Lepej, S. Z. and Boucher, C. A. Wensing, A. M. Perno, C. F. Svicher, V. and European Soc Translational

Published
2016

21. Combined analysis of the prevalence of drug-resistant Hepatitis B virus in antiviral therapy-experienced patients in Europe (CAPRE)

Author

Hermans, L.E. Svicher, V. Pas, S.D. Salpini, R. Alvarez, M. Ben Ari, Z. Boland, G. Bruzzone, B. Coppola, N. Seguin-Devaux, C. Dyda, T. Garcia, F. Kaiser, R. Köse, S. Krarup, H. Lazarevic, I. Lunar, M.M. Maylin, S. Micheli, V. Mor, O. Paraschiv, S. Paraskevis, D. Poljak, M. Puchhammer-Stöckl, E. Simon, F. Stanojevic, M. Stene-Johansen, K. Tihic, N. Trimoulet, P. Verheyen, J. Vince, A. Weis, N. Yalcinkaya, T. Lepej, S.Z. Perno, C. Boucher, C.A.B. Wensing, A.M.J.

Abstract

Background European guidelines recommend treatment of chronic hepatitis B virus infection (CHB) with the nucleos(t)ide analogs (NAs) entecavir or tenofovir. However, many European CHB patients have been exposed to other NAs, which are associated with therapy failure and resistance. The CAPRE study was performed to gain insight in prevalence and characteristics of NA resistance in Europe. Methods A survey was performed on genotypic resistance testing results acquired during routine monitoring of CHB patients with detectable serum hepatitis B virus DNA in European tertiary referral centers. Results Data from 1568 patients were included. The majority (73.8%) were exposed to lamivudine monotherapy. Drug-resistant strains were detected in 52.7%. The most frequently encountered primary mutation was M204V/I (48.7%), followed by A181T/V (3.8%) and N236T (2.6%). In patients exposed to entecavir (n = 102), full resistance was present in 35.3%. Independent risk factors for resistance were age, viral load, and lamivudine exposure (P

Published
2016

22. IMMUNE-ESCAPE MUTATIONS AND STOP-CODONS IN HBSAG CIRCULATES IN A RELEVANT PROPORTION OF PATIENTS WITH CHRONIC HBV INFECTION EXPOSED TO ANTI-HBV DRUGS IN EUROPE: IMPLICATIONS FOR HBV TRANSMISSION IN THE SETTING OF VACCINATION AND DISEASE PROGRESSION

Author

Colagrossi, L., Hermans, L. E., Salpini, R., Pas, S. D., Alvarez, M., Ben Ari, Z., Boland, G., Bruzzone, B., Coppola, N., Seguin-Devaux, C., Dyda, T., Garcia, F., Kaiser, R., Kose, S., Krarup, H., Lazarevic, I., Lunar, M. M., Maylin, S., Micheli, V., Mor, O., Paraschiv, S., Paraskevis, D., Poljak, M., Puchhammer-Stoeckl, E., Simon, F., Stanojevic, M., Stene-Johansen, K., Tihic, N., Trimoulet, P., Verheyen, J., Vince, A., Weis, N., Yalcinkaya, T., Lepej, S. Z., Boucher, C. A., Wensing, A. M., Perno, C. F., Svicher, V., Colagrossi, L., Hermans, L. E., Salpini, R., Pas, S. D., Alvarez, M., Ben Ari, Z., Boland, G., Bruzzone, B., Coppola, N., Seguin-Devaux, C., Dyda, T., Garcia, F., Kaiser, R., Kose, S., Krarup, H., Lazarevic, I., Lunar, M. M., Maylin, S., Micheli, V., Mor, O., Paraschiv, S., Paraskevis, D., Poljak, M., Puchhammer-Stoeckl, E., Simon, F., Stanojevic, M., Stene-Johansen, K., Tihic, N., Trimoulet, P., Verheyen, J., Vince, A., Weis, N., Yalcinkaya, T., Lepej, S. Z., Boucher, C. A., Wensing, A. M., Perno, C. F., and Svicher, V.

Published
2016

23. Intensification with pegylated interferon during treatment with tenofovir in HIV–hepatitis B virus co‐infected patients

Author

Boyd, A., primary, Piroth, L., additional, Maylin, S., additional, Maynard‐Muet, M., additional, Lebossé, F., additional, Bouix, C., additional, Lascoux‐Combe, C., additional, Mahjoub, N., additional, Girard, P.‐M., additional, Delaugerre, C., additional, Carrat, F., additional, Lacombe, K., additional, and Miailhes, P., additional

Published
2016
Full Text
View/download PDF

25. Immunosuppression-driven HBV reactivation in patients with resolved HBV infection correlates with a relevant risk of death and with evolution towards active chronical infection

Author

Battisti, A., primary, Salpini, R., additional, Colagrossi, L., additional, Alteri, C., additional, Pollicita, M., additional, Ricciardi, A., additional, Cerva, C., additional, Maffongelli, G., additional, Lichtner, M., additional, Mastroianni, C., additional, Casinelli, K., additional, Paoloni, M., additional, Marignani, M., additional, Maylin, S., additional, Delaugerre, C., additional, Morisco, F., additional, Coppola, N., additional, Marrone, A., additional, Brega, A., additional, Francioso, S., additional, Venditti, A., additional, Mari, T., additional, Mazzoni, E., additional, Iapadre, N., additional, Di Paolo, D., additional, Sarrecchia, C., additional, Sarmati, L., additional, Andreoni, M., additional, Taliani, G., additional, Angelico, M., additional, Perno, C.F., additional, and Svicher, V., additional

Published
2016
Full Text
View/download PDF

26. Immune-Escape Mutations and Stop-Codons in HBsAg Circulates in a Relevant Proportion of Patients with Chronic HBV Infection Exposed to Anti-HBV Drugs in Europe: Implications for HBV Transmission in the Setting of Vaccination and Disease Progression

Author

Colagrossi, L., primary, Hermans, L.E., additional, Salpini, R., additional, Pas, S.D., additional, Alvarez, M., additional, Ben Ari, Z., additional, Boland, G., additional, Bruzzone, B., additional, Coppola, N., additional, Seguin-Devaux, C., additional, Dyda, T., additional, Garcia, F., additional, Kaiser, R., additional, Köse, S., additional, Krarup, H., additional, Lazarevic, I., additional, Lunar, M.M., additional, Maylin, S., additional, Micheli, V., additional, Mor, O., additional, Paraschiv, S., additional, Paraskevis, D., additional, Poljak, M., additional, Puchhammer-Stöckl, E., additional, Simon, F., additional, Stanojevic, M., additional, Stene-Johansen, K., additional, Tihic, N., additional, Trimoulet, P., additional, Verheyen, J., additional, Vince, A., additional, Weis, N., additional, Yalcinkaya, T., additional, Lepej, S.Z., additional, Boucher, C.A., additional, Wensing, A.M., additional, Perno, C.F., additional, and Svicher, V., additional

Published
2016
Full Text
View/download PDF

27. A HYPER-GLYCOSYLATION OF HBV SURFACE MAJOR HYDROPHILIC REGION CORRELATES WITH IMMUNOSUPPRESSION-DRIVEN HBV REACTIVATION AND HAMPERS HBSAG RECOGNITION IN VITRO

Author

Colagrossi, L., Salpini, R., Surdo, M., Battisti, A., Pollicita, M., Bertoli, A., Di Santo, F., Becker, C., Mastroianni, C., Marignani, M., Maylin, S., Delaugerre, C., Morisco, F., Coppola, N., Marrone, A., Sarmati, L., Andreoni, M., Angelico, M., Verheyen, J., Perno, C. F., Svicher, V., Colagrossi, L., Salpini, R., Surdo, M., Battisti, A., Pollicita, M., Bertoli, A., Di Santo, F., Becker, C., Mastroianni, C., Marignani, M., Maylin, S., Delaugerre, C., Morisco, F., Coppola, N., Marrone, A., Sarmati, L., Andreoni, M., Angelico, M., Verheyen, J., Perno, C. F., and Svicher, V.

Published
2015

28. SAT-350 - A hyper-glycosylation of HBV surface antigen characterizes immunosuppression-driven HBV reactivation and hinders HBsAg recognition in vitro

Author

Salpini, R., Piermatteo, L., Battisti, A., Colagrossi, L., Aragri, M., Fabeni, L., Bertoli, A., Mastroianni, C.M., Marignani, M., Maylin, S., Delaugerre, C., Morisco, F., Nicola, C., Marrone, A., Iapadre, N., Mario, A., Sarmati, L., Andreoni, M., Verheyen, J., Silberstein, F.C., Levrero, M., Perno, C.F., Belloni, L., and Svicher, V.

Published
2018
Full Text
View/download PDF

29. Precore G1896A mutation is associated with reduced rates of HBsAg seroclearance in treated HIV hepatitis B virus co‐infected patients from Western Africa.

Author

Boyd, A., Moh, R., Maylin, S., Abdou Chekaraou, M., Mahjoub, N., Gabillard, D., Anglaret, X., Eholié, S. P., Delaugerre, C., Danel, C., Zoulim, F., and Lacombe, K.

Subjects
NUCLEOTIDE separation, GENETIC mutation, HEPATITIS B virus, ANTIVIRAL agents, POLYPEPTIDES
Abstract

Summary: The nucleotide substitution G1896A on the precore (pc) region has been implicated in virological and serological responses during treatment in hepatitis B virus (HBV)‐infected patients. Whether this mutation affects the therapeutic course of HIV‐HBV co‐infected patients, especially from Western Africa, is unknown. In this prospective cohort study, 86 antiretroviral (ARV)‐naïve HIV‐HBV co‐infected patients from Côte d'Ivoire, initiating ARV‐treatment containing lamivudine (n = 53) or tenofovir (n = 33), had available baseline pc sequences. Association of the pcG1896A mutation with time to undetectable HBV‐DNA, hepatitis B "e" antigen (HBeAg) seroclearance (in HBeAg‐positive patients), and hepatitis B surface antigen (HBsAg) seroclearance was evaluated using Cox proportional hazards regression. At ARV‐initiation, median HBV‐DNA was 6.04 log10 copies/mL (IQR = 3.70‐7.93) with 97.7% harbouring HBV genotype E. Baseline pcG1896A mutation was identified in 51 (59.3%) patients, who were more commonly HBeAg‐negative (P < .001) and had basal core promotor A1762T/G1764A mutations (P < .001). Patients were followed for a median 36 months (IQR = 24‐36). Cumulative proportion of undetectable HBV‐DNA was significantly higher in patients with baseline mutation (pcG1896A = 86.6% vs no pcG1896A = 66.9%, P = .04), but not after adjusting for baseline HBV‐DNA levels and anti‐HBV agent (P = .2). No difference in cumulative proportion of HBeAg seroclearance was observed between mutation groups (pcG1896A = 57.1% vs no pcG1896A = 54.3%, P = .7). Significantly higher cumulative proportion of HBsAg seroclearance was observed in patients without this mutation (pcG1896A = 0% vs no pcG1896A = 36.9%, P < .001), even after adjusting for baseline HBsAg quantification and anti‐HBV agent (P < .001). In conclusion, lacking the pcG1896A mutation before ARV initiation appeared to increase HBsAg seroclearance rates during treatment. The therapeutic implications of this mutation need further exploration in this setting. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

30. P0580 : Genetic signatures specifically clustered in immune active HBsAg regions correlate with immunosuppression-driven HBV reactivation: An extensive analysis of HBV genome

Author

Svicher, V., primary, Salpini, R., additional, Colagrossi, L., additional, Battisti, A., additional, Bellocchi, M.C., additional, Alteri, C., additional, Armenia, D., additional, Di Santo, F., additional, Carioti, L., additional, Pollicita, M., additional, Ricciardi, A., additional, Lichtner, M., additional, Mastroianni, C., additional, Paoloni, M., additional, Marignani, M., additional, Maylin, S., additional, Delaugerre, C., additional, Morisco, F., additional, Coppola, N., additional, Marrone, A., additional, Di Paolo, D., additional, Sarrecchia, C., additional, Sarmati, L., additional, Andreoni, M., additional, Angelico, M., additional, and Perno, C.F., additional

Published
2015
Full Text
View/download PDF

31. P0625 : A hyper-glycosylation of HBV surface major hydrophilic region characterizes HBV reactivation driven by immunosuppression and affects HBsAg recognition in vitro

Author

Salpini, R., primary, Surdo, M., additional, Colagrossi, L., additional, Battisti, A., additional, Pollicita, M., additional, Bertoli, A., additional, Di Santo, F., additional, Becker, C., additional, Mastroianni, C., additional, Marignani, M., additional, Maylin, S., additional, Delaugerre, C., additional, Morisco, F., additional, Coppola, N., additional, Marrone, A., additional, Sarmati, L., additional, Andreoni, M., additional, Angelico, M., additional, Verheyen, J., additional, Perno, C.F., additional, and Svicher, V., additional

Published
2015
Full Text
View/download PDF

32. A hyper-glycosylation of HBV surface major hydrophilic region correlates with immunosuppression-driven HBV reactivation and hampers HBsAg recognition in vitro

Author

Colagrossi, L., primary, Salpini, R., additional, Surdo, M., additional, Battisti, A., additional, Pollicita, M., additional, Bertoli, A., additional, Di Santo, F., additional, Becker, C., additional, Mastroianni, C., additional, Marignani, M., additional, Maylin, S., additional, Delaugerre, C., additional, Morisco, F., additional, Coppola, N., additional, Marrone, A., additional, Sarmati, L., additional, Andreoni, M., additional, Angelico, M., additional, Verheyen, J., additional, Perno, C.F., additional, and Svicher, V., additional

Published
2015
Full Text
View/download PDF

34. THU-136 - Immune-Escape Mutations and Stop-Codons in HBsAg Circulates in a Relevant Proportion of Patients with Chronic HBV Infection Exposed to Anti-HBV Drugs in Europe: Implications for HBV Transmission in the Setting of Vaccination and Disease Progression

Author

Colagrossi, L., Hermans, L.E., Salpini, R., Pas, S.D., Alvarez, M., Ben Ari, Z., Boland, G., Bruzzone, B., Coppola, N., Seguin-Devaux, C., Dyda, T., Garcia, F., Kaiser, R., Köse, S., Krarup, H., Lazarevic, I., Lunar, M.M., Maylin, S., Micheli, V., Mor, O., Paraschiv, S., Paraskevis, D., Poljak, M., Puchhammer-Stöckl, E., Simon, F., Stanojevic, M., Stene-Johansen, K., Tihic, N., Trimoulet, P., Verheyen, J., Vince, A., Weis, N., Yalcinkaya, T., Lepej, S.Z., Boucher, C.A., Wensing, A.M., Perno, C.F., and Svicher, V.

Published
2016
Full Text
View/download PDF

35. Transmission verticale du virus de l’hépatite B (VHB) malgré la sérovaccination des nouveaux-nés de mères d’origines ethniques différentes mono-inféctées par le VHB avec une charge virale élevée :étude rétrospective à Paris

Author

Lopes, A., primary, Maylin, S., additional, Moreno, M.-D., additional, Amarsy, R., additional, Ricbourg, A., additional, Delcey, V., additional, Mazeron, M.-C., additional, Mouly, S., additional, Barranger, E., additional, Simon, F., additional, Bergmann, J.-F., additional, and Sellier, P., additional

Published
2013
Full Text
View/download PDF

36. 428 VERTICAL HEPATITIS B VIRUS TRANSMISSION DESPITE SEROVACCINATION OF THE NEWBORN IN HIGHLY VIRAEMIC MONO-INFECTED MOTHERS FROM VARIOUS ETHNIC ORIGINS: A RETROSPECTIVE STUDY IN PARIS, FRANCE

Author

Sellier, P., primary, Maylin, S., additional, Moreno, M., additional, Ricbourg, A., additional, Mazeron, M.-C., additional, Lopes, A., additional, Simoneau, G., additional, Magnier, J.-D., additional, Barranger, E., additional, Simon, F., additional, and Bergmann, J.-F., additional

Published
2013
Full Text
View/download PDF

37. Multicenter Quality Control of Hepatitis C Virus Protease Inhibitor Resistance Genotyping

Author

Vallet, S., primary, Larrat, S., additional, Laperche, S., additional, Le Guillou-Guillemette, H., additional, Legrand-Abravanel, F., additional, Bouchardeau, F., additional, Pivert, A., additional, Henquell, C., additional, Mirand, A., additional, Andre-Garnier, E., additional, Giordanengo, V., additional, Lagathu, G., additional, Thibault, V., additional, Scholtes, C., additional, Schvoerer, E., additional, Gaudy-Graffin, C., additional, Maylin, S., additional, Trimoulet, P., additional, Brochot, E., additional, Hantz, S., additional, Gozlan, J., additional, Roque-Afonso, A.-M., additional, Soussan, P., additional, Plantier, J.-C., additional, Charpentier, C., additional, Chevaliez, S., additional, Colson, P., additional, Mackiewicz, V., additional, Aguilera, L., additional, Rosec, S., additional, Gouriou, S., additional, Magnat, N., additional, Lunel-Fabiani, F., additional, Izopet, J., additional, Morand, P., additional, Payan, C., additional, and Pawlotsky, J.-M., additional

Published
2013
Full Text
View/download PDF

39. 777 SUSTAINED VIROLOGICAL RESPONSE IS ASSOCIATED WITH A LOWER RISK OF COMPLICATIONS AND HEPATOCELLULAR CARCINOMA IN PATIENTS WITH HCV RELATED CIRRHOSIS

Author

Cardoso, A.C., primary, Moucari, R., additional, Giuily, N., additional, Figueiredo-Mendes, C., additional, Boyer, N., additional, Ripault, M.P., additional, Castelnau, C., additional, Asselah, T., additional, Martinot-Peignoux, M., additional, Maylin, S., additional, Bedossa, P., additional, and Marcellin, P., additional

Published
2008
Full Text
View/download PDF

40. 808 ASSESSMENT OF VIROLOGICAL RESPONSE AT BOTH WEEK 4 AND WEEK 12 OPTIMIZES PREDICTION OF PEGINTERFERON ALFA PLUS RIBAVIRIN.TREATMENT IN PATIENTS WITH CHRONIC HEPATITIS C

Author

Martinot-Peignoux, M., primary, Ripault, M.P., additional, Moucari, R., additional, Boyer, N., additional, Maylin, S., additional, Cardoso, A.C., additional, Giuily, N., additional, Castelnau, C., additional, Pouteau, M., additional, Bedossa, P., additional, and Marcellin, P., additional

Published
2008
Full Text
View/download PDF

48. A snapshot of virological presentation and outcome of immunosuppression-driven HBV reactivation from real clinical practice: Evidence of a relevant risk of death and evolution from silent to chronic infection

Author

Romina Salpini, Arianna Battisti, Luna Colagrossi, Domenico Di Carlo, Lavinia Fabeni, Lorenzo Piermatteo, Carlotta Cerva, Miriam Lichtner, Claudio Mastroianni, Massimo Marignani, Sarah Maylin, Constance Delaugerre, Filomena Morisco, Nicola Coppola, Aldo Marrone, Mario Angelico, Loredana Sarmati, Massimo Andreoni, Carlo‐Federico Perno, Francesca Ceccherini‐Silberstein, Valentina Svicher, Ada Bertoli, Vanessa Fini, Michela Pollicita, Gaetano Maffongelli, Alessandra Ricciardi, Cesare Sarrecchia, Leonardo Baiocchi, Arianna Brega, null Daniele Di Paolo, Simona Francioso, Ilaria Lenci, William Arcese, Laura Cudillo, Benedetta Mariotti, null Claudio Miriam Lichtner, Raffaella Marocco, Maria Mastroianni, Gloria Taliani, Tiziana Tieghi, Maria Rosaria Esposito, Terenzio Mari, Ettore Mazzoni, Fabrizio Spaziani, Katia Casinelli, Maurizio Paoloni, Nerio Iapadre, Alessandro Grimaldi, Paola Begini, Barbara Imperatrice, Luigi Vanvitelli, Margherita Macera, Mariantonietta Pisaturo, Chiara more, Isabella Siniscalchi, Salpini, R, Battisti, A, Colagrossi, L, Di Carlo, D, Fabeni, L, Piermatteo, L, Cerva, C, Lichtner, M, Mastroianni, C, Marignani, M, Maylin, S, Delaugerre, C, Morisco, F, Coppola, N, Marrone, A, Angelico, M, Sarmati, L, Andreoni, M, Perno, Cf, Ceccherini-Silberstein, F, Svicher, V, Salpini, R., Battisti, A., Colagrossi, L., Di Carlo, D., Fabeni, L., Piermatteo, L., Cerva, C., Lichtner, M., Mastroianni, C., Marignani, M., Maylin, S., Delaugerre, C., Morisco, F., Coppola, N., Marrone, A., Angelico, M., Sarmati, L., Andreoni, M., Perno, C. -F., Ceccherini-Silberstein, F., and Svicher, V.

Subjects
Male, Hepatitis B virus, HBsAg, medicine.medical_specialty, Genotype, Settore MED/17 - Malattie Infettive, medicine.medical_treatment, Treatment outcome, Hbv reactivation, HBV reactivation, Immunocompromised Host, 03 medical and health sciences, Hepatitis B, Chronic, HBV chronicity, Immunosuppression, antiviral prophylaxis, 0302 clinical medicine, Virology, Internal medicine, Humans, Medicine, 030212 general & internal medicine, Hepatitis B Surface Antigens, Hepatology, business.industry, Genetic Variation, virus diseases, Viral Load, Hepatitis B, digestive system diseases, Clinical Practice, Chronic infection, Treatment Outcome, Infectious Diseases, Disease Progression, Female, Virus Activation, 030211 gastroenterology & hepatology, Rituximab, antiviral prophylaxi, Risk of death, business, hbv chronicity, hbv reactivation, immunosuppression, Immunosuppressive Agents, medicine.drug
Abstract

The study was undertaken in order to provide a snapshot from real clinical practice of virological presentation and outcome of patients developing immunosuppression-driven HBV reactivation. Seventy patients with HBV reactivation were included (66.2% treated with rituximab, 10% with corticosteroids and 23.8% with other immunosuppressive drugs). Following HBV reactivation, patients received anti-HBV treatment for a median (IQR) follow-up of 31(13-47) months. At baseline-screening, 72.9% of patients were HBsAg-negative and 27.1% HBsAg-positive. About 71.4% had a diagnosis of biochemical reactivation [median (IQR) HBV DNA and ALT: 6.9 (5.4-7.8) log IU/mL and 359 (102-775) U/L]. Moreover, 10% of patients died from hepatic failure. Antiviral prophylaxis was documented in 57.9% and 15.7% of HBsAg-positive and HBsAg-negative patients at baseline-screening (median [IQR] prophylaxis duration: 24[15-33] and 25[17-36] months, respectively). Notably, HBV reactivation occurred 2-24 months after completing the recommended course of anti-HBV prophylaxis in 35.3% of patients. By analysing treatment outcome, the cumulative probability of ALT normalization and of virological suppression was 97% and 69%, respectively. Nevertheless, in patients negative to HBsAg at baseline-screening, only 27% returned to HBsAg-negative status during prolonged follow-up, suggesting the establishment of chronic infection. In conclusion, most patients received a diagnosis of HBV reactivation accompanied by high ALT and 10% died for hepatic failure, supporting the importance of strict monitoring for an early HBV reactivation diagnosis. Furthermore, HBV reactivation correlates with high risk of HBV chronicity in patients negative for HBsAg at baseline-screening, converting a silent into a chronic infection, requiring long-term antiviral treatment. Finally, a relevant proportion of patients experienced HBV reactivation after completing the recommended course of anti-HBV prophylaxis, suggesting the need to reconsider proper duration of prophylaxis particularly in profound immunosuppression.

Published
2019

49. A hyper-glycosylation of HBV surface antigen correlates with HBsAg-Negativity at immunosuppression-driven HBV reactivation in vivo and hinders HBsAg recognition in vitro

Author

Francesca Ceccherini-Silberstein, Carlotta Cerva, Ada Bertoli, Carlo Federico Perno, Massimo Marignani, Miriam Lichtner, Aldo Marrone, L. Colagrossi, Jens Verheyen, Valentina Svicher, Katia Yu La Rosa, N. Iapadre, Constance Delaugerre, L. Piermatteo, Massimo Levrero, Sarah Maylin, Marianna Aragri, Nicola Coppola, Loredana Sarmati, Stefano Aquaro, A. Battisti, Romina Salpini, Laura Belloni, Massimo Andreoni, Mario Angelico, Patrizia Saccomandi, Filomena Morisco, Salpini, R., Piermatteo, L., Battisti, A., Colagrossi, L., Aragri, M., Rosa, K. Y. L., Bertoli, A., Saccomandi, P., Lichtner, M., Marignani, M., Maylin, S., Delaugerre, C., Morisco, F., Coppola, N., Marrone, A., Iapadre, N., Cerva, C., Aquaro, S., Angelico, M., Sarmati, L., Andreoni, M., Verheyen, J., Ceccherini-Silberstein, F., Levrero, M., Perno, C. F., Belloni, L., Svicher, V., Salpini, Romina, Piermatteo, Lorenzo, Battisti, Arianna, Colagrossi, Luna, Aragri, Marianna, Yu La Rosa, Katia, Bertoli, Ada, Saccomandi, Patrizia, Lichtner, Miriam, Marignani, Massimo, Maylin, Sarah, Delaugerre, Constance, Morisco, Filomena, Coppola, Nicola, Marrone, Aldo, Iapadre, Nerio, Cerva, Carlotta, Aquaro, Stefano, Angelico, Mario, Sarmati, Loredana, Andreoni, Massimo, Verheyen, Jen, Ceccherini-Silberstein, Francesca, Levrero, Massimo, Federico Perno, Carlo, Belloni, Laura, and Svicher, Valentina

Subjects
0301 basic medicine, Male, HBsAg, Glycosylation, lcsh:QR1-502, Medizin, medicine.disease_cause, lcsh:Microbiology, HBV, HBV reactivation, N-linked glycosylation, 0302 clinical medicine, biology, virus diseases, Middle Aged, Infectious Diseases, 030211 gastroenterology & hepatology, Female, Antibody, Hepatitis B virus, Article, Cell Line, 03 medical and health sciences, Antigen, In vivo, Virology, medicine, Humans, Hepatitis B Antibodies, Aged, Immune Evasion, Hepatitis, Immunosuppression Therapy, Hepatitis B Surface Antigens, business.industry, medicine.disease, In vitro, Settore MED/17, digestive system diseases, 030104 developmental biology, Reinfection, Mutation, biology.protein, Virus Activation, business
Abstract

Immune-suppression driven Hepatitis B Virus (HBV)-reactivation poses serious concerns since it occurs in several clinical settings and can result in severe forms of hepatitis. Previous studies showed that HBV strains, circulating in patients with HBV-reactivation, are characterized by an enrichment of immune-escape mutations in HBV surface antigen (HBsAg). Here, we focused on specific immune-escape mutations associated with the acquisition of N-linked glycosylation sites in HBsAg (NLGSs). In particular, we investigated profiles of NLGSs in 47 patients with immunosuppression-driven HBV-reactivation and we evaluated their impact on HBsAg-antigenicity and HBV-replication in vitro. At HBV-reactivation, despite a median serum HBV-DNA of 6.7 [5.3&ndash, 8.0] logIU/mL, 23.4% of patients remained HBsAg-negative. HBsAg-negativity at HBV-reactivation correlated with the presence of &gt, 1 additional NLGSs (p &lt, 0.001). These NLGSs are located in the major hydrophilic region of HBsAg (known to be the target of antibodies) and resulted from the single mutation T115N, T117N, T123N, N114ins, and from the triple mutant S113N+T131N+M133T. In vitro, NLGSs strongly alter HBsAg antigenic properties and recognition by antibodies used in assays for HBsAg-quantification without affecting HBsAg-secretion and other parameters of HBV-replication. In conclusion, additional NLGSs correlate with HBsAg-negativity despite HBV-reactivation, and hamper HBsAg-antigenicity in vitro, supporting the role of NGSs in immune-escape and the importance of HBV-DNA for a proper diagnosis of HBV-reactivation.

Published
2020

50. Human Immunodeficiency Virus Type 1 Group O Infection in France: Clinical Features and Immunovirological Response to Antiretrovirals

Author

Henri Panjo, Guillemette Unal, François Simon, Jean-Christophe Plantier, Elodie Alessandri-Gradt, Diane Descamps, Charlotte Charpentier, Juliette Pavie, Marie Leoz, Francis Barin, Laurence Meyer, Clément Lefèvre, Orivao Study, Groupe de Recherche sur l'Adaptation Microbienne (GRAM 2.0), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Université de Caen Normandie (UNICAEN), Normandie Université (NU), Centre de recherche en épidémiologie et santé des populations (CESP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Université Paris Descartes - Faculté de Médecine (UPD5 Médecine), Université Paris Descartes - Paris 5 (UPD5), Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Infection, Anti-microbiens, Modélisation, Evolution (IAME (UMR_S_1137 / U1137)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris 13 (UP13)-Université Paris Diderot - Paris 7 (UPD7)-Université Sorbonne Paris Cité (USPC), Morphogénèse et antigénicité du VIH et du virus des Hépatites (MAVIVH - U1259 Inserm - CHRU Tours ), Université de Tours-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Régional Universitaire de Tours (CHRU TOURS), Faculté de Médecine [Université Paris Diderot - Paris 7], Université Paris Diderot - Paris 7 (UPD7), Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), ORIVAO Study : Chennebault J, Fialaire P, Le Guillou-Guillemette H, Rehaiem S, Chanzy B, Clavere G, Gaillat J, Courdavault L, Genet P, Gerbe J, Benoit C, Honore Bouakline S, Waldner A, Bettinger D, Chirouze C, Bernard N, Reigadas S, Dupont X, Gaillard JL, Gault E, Reimann E, Otterbein G, Thomas L, Vaghefi P, Benoit M, Buthiot N, Goux A, Chambrin V, Deback C, Fior R, Raho Moussa M, Antoniotti O, Coban D, Cormerais L, Henquell C, Jacomet C, Lesens O, Chanoine N, Villmant A, Van Autreve JL, Bloch M, Ichou H, Manceron V, Mortier E, Zeng A, Bouvier-Alias M, Dominguez S, Lascaux-Cametez AS, Lelievre JD, Levy Y, Melica-Gregoire G, Pawlotsky JM, Pothier P, Waldner A, Inchiappa L, Verhaeghe A, Olivier B, Pathe JP, Berthe H, Mathez D, Favret V, Troisvallets D, Vandemeulebroucke E, Ceccaldi J, El Harif Z, Bocket L, Barbut P, Chaix F, Lambert C, Lambolez T, Miatezila J, Son O, Brunet P, Chappe C, Dhiver C, Lecomte V, Meddeb L, Poizot-Martin I, Tamalet C, Valadier J, Beck-Wirth G, Benomar M, Delarbre JM, Peter JM, Bevilacqua S, Venard V, Daneluzzi V, Idri N, Montoya B, Ferre V, Garnier E, Hue H, Larmet L, Point P, Raffi F, Reliqiet V, Rodallec A, Secher S, Amoyel P, Botton E, Janowski M, Le Cocguic Y, Deleplanque P, Descamps JM, Lapine M, Sunder S, Chansombat M, Charpentier C, Damond F, Diallo B, Duval X, Julia Z, Landman R, Legac S, Rioux C, Yeni P, Krivine A, Blanche P, Cros A, Gazalet P, Ghosn J, Krivine A, Sobel A, Bercot B, Diemer M, Parrinello M, Bey Boumezrag C, Bodard L, Gibert S, Huche FX, Raffenne L, Strebler M, Blanc C, Bourzam E, Hansel B, Lupin C, Wirden M, Bourzam E, Collias L, Effa J, Jung C, Pavie J, Pere H, Si Mohamed A, Delaugerre C, Gerard L, Loze B, Maylin S, Nabias R, Ponscarme D, Deleuze J, Rozenberg F, Bachour B, Bani-Sadr F, Chas J, Hamidi M, Kherallah L, Le Nagat S, Le Pendeven C, Moreau F, Nicolas JC, Schneider V, Tabone MD, Vaudre G, Giraudeau G, Le Moal G, Plainchamp D, Blondin G, Dorval I, Duthe JC, Perfezou P, Berger JL, Brodard V, Kmiec I, Rouger C, Strady C, Chappelin JM, Maillard A, Ratajczak M, Debab Y, De Oliveira F, Depatureaux A, Gueit I, Lemee V, Theron D, Pasdeloup I, Camps P, Bigaillon C, Ficko C, Imbert C, Rapp C, Grand C, Michau C, Bornarel D, Devillier P, Farfour E, Majerholc C, Vignon D, Zucman D, El Addouli M, Danjoux MF, Journe J, Leveneur Y, Marchou B, Nicot F, Prevoteau Du Clary F, Bonne S., Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Paris 13 (UP13)-Université Paris Diderot - Paris 7 (UPD7)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), and Dupuis, Christine

Subjects
0301 basic medicine, Microbiology (medical), Cart, Adult, Male, medicine.medical_specialty, Anti-HIV Agents, Human immunodeficiency virus (HIV), HIV Infections, medicine.disease_cause, Gastroenterology, 03 medical and health sciences, Internal medicine, Medicine, Humans, Protease inhibitor (pharmacology), Survival analysis, Reverse-transcriptase inhibitor, business.industry, Genetic Variation, Middle Aged, Viral Load, 030112 virology, Antiretroviral therapy, 3. Good health, CD4 Lymphocyte Count, Regimen, 030104 developmental biology, Infectious Diseases, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, HIV-1, Female, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, France, business, Viral load, medicine.drug
Abstract

International audience; Background:To obtain reliable clinical data of human immunodeficiency virus type 1 group O (HIV-1/O) infection, and immunovirological responses to combination antiretroviral therapy (cART), in a large series of 101 patients.Methods:Piecewise linear models were used to estimate CD4 count before and after cART initiation. Kaplan-Meier survival curves were used to estimate time to reach clinical stage C before antiretroviral therapy (ART) and to analyze time to achieve a plasma viral load (pVL)

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results